SCHEMBL19995074

SCHEMBL19995074

CN[C@H]1C[C@](O)(C(F)(F)F)C1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.33
IL1B P01584 1/20 0.33
HSD11B1 P28845 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21407135 1.00 TNF (0.33) TNFIL1BHSD11B1
SCHEMBL19766546 0.77 HSD11B1 (0.33) TNFIL1BHSD11B1
SCHEMBL22482082 0.74 ATM (0.37) TNFIL1BHSD11B1
SCHEMBL22482090 0.74 ATM (0.37) TNFIL1BHSD11B1
SCHEMBL22887047 0.74 HSD11B1 (0.35) HSD11B1
SCHEMBL21948554 0.74 HSD11B1 (0.35) HSD11B1
SCHEMBL20727450 0.74 HSD11B1 (0.35) HSD11B1
SCHEMBL27310041 0.73 HSD11B1 (0.37) TNFIL1BHSD11B1
SCHEMBL12108434 0.72 HSD11B1 (0.34) HSD11B1
SCHEMBL23573544 0.71 TNF (0.32) TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515913-B1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2022-05-11 EP disclosed
US-11203595-B2 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG (CH) 2021-12-21 US disclosed
US-20210188842-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-06-24 US disclosed
US-10766894-B2 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG (CH) 2020-09-08 US disclosed
US-20190300522-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. 2019-10-03 US disclosed
EP-3515913-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
WO-2018055551-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766894-B2 Aza-indazole compounds for use in tendon and/or ligament injuries MMP1, TIMP3, ALPI TNF 1336/4885IL1B 314/4885HSD11B1 220/4885
US-20190300522-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES MMP1, TIMP3, ALPI TNF 1336/4885IL1B 314/4885HSD11B1 220/4885
US-20210188842-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES MMP1, ALPI, TIMP3 TNF 1242/4885IL1B 303/4885HSD11B1 221/4885
US-11203595-B2 Aza-indazole compounds for use in tendon and/or ligament injuries MMP1, ALPI, TIMP3 TNF 1242/4885IL1B 303/4885HSD11B1 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.